Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
253.25
-2.29 (-0.90%)
Jun 15, 2026, 4:00 PM EDT - Market closed

Ligand Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 10 analysts polled by S&P Global, Ligand Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $277.6. The average 1-year stock price forecast is 9.62% higher than the current stock price, while the lowest is $247 (-2.47%) and the highest is $330 (+30.31%).

Price Target: $277.6 (+9.62%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$247$277.6$278.5$330
Change-2.47%+9.62%+9.97%+30.31%

Analyst Ratings

The average analyst rating for Ligand Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingDec '25Jan '26Feb '26Mar '26Apr '26May '26
Strong Buy666777
Buy222222
Hold000000
Sell000000
Strong Sell000000
Total888999

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Craig-Hallum
Craig-Hallum
Buy
Maintains
n/a
BuyMaintainsn/an/aJun 3, 2026
Bank of America Securities
Bank of America Securities
Buy
Maintains
$266
BuyMaintains$266+5.03%Jun 2, 2026
RBC Capital
RBC Capital
Buy
Reiterates
$262
BuyReiterates$262+3.46%May 12, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$289
BuyReiterates$289+14.12%May 7, 2026
Stifel Nicolaus
Stifel Nicolaus
Buy
Reiterates
$230$255
BuyReiterates$230$255+0.69%Apr 27, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
286.10M
from 268.09M
Increased by 6.72%
Revenue Next Year
363.63M
from 286.10M
Increased by 27.10%
EPS This Year
9.10
from 8.13
Increased by 11.95%
EPS Next Year
11.32
from 9.10
Increased by 24.34%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
241.54M196.25M131.31M167.13M268.09M286.10M
Revenue Growth
47.68%-18.75%-33.09%27.28%60.40%6.72%
Gross Profit
147.26M107.34M96.27M134.63M172.36M253.42M
Gross Margin
60.97%54.69%73.31%80.56%64.29%88.58%
Operating Income
66.25M3.04M9.82M23.02M47.20M142.62M
Net Income
57.14M-33.36M52.15M-4.03M124.45M92.13M
EPS
----8.139.10
EPS Growth
-----1.45%11.95%
Forward PE
--35.0753.5835.2027.83
Free Cash Flow
37.03M136.93M46.03M100.79M87.09M146.12M
No. Analysts
-----9
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High309.7M
Avg286.1M
Low273.6M

Revenue Growth

Revenue Growth202620272028
High
15.5%
Avg
6.7%
Low
2.1%

EPS Forecast

EPS202620272028
High-
Avg9.10
Low-

EPS Growth

EPS Growth202620272028
High-
Avg
11.9%
Low-